|
1
|
Rubenstein JH and Shaheen NS:
Epidemiology, diagnosis, and management of esophageal
adenocarcinoma. Gastroenterology. 149:302–317.e1. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lagergren J, Smyth E, Cunninham G and
Lagergren P: Oesophageal cancer. Lancet. 390:2383–2396. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riddiough GE, Hornby ST, Asadi K and Aly
A: Gastric adenocarcinoma of the upper oesophagus: A literature
review and case report. Int J Surg Case Rep. 30:205–214. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dziadkowiec KN, Sánchez-Luna SA, Stawinski
P and Proenza J: Adenocarcinoma arising from a cervical esophageal
inlet patch: The malignant potential of a small lesion. Cureus.
12:e92842020.PubMed/NCBI
|
|
5
|
Ninomiya I, Okamoto K, Yamaguchi T, Saito
H, Terai S, Moriyama H, Kinoshita J and Fushida S: Optimization of
robot-assisted thoracoscopic esophagectomy in the lateral decubitus
position. Esophagus. 18:482–488. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peitz U, Vieth M, Evert M, Arand J,
Roessner A and Malfertheiner P: The prevalence of gastric
heterotopia of the proximal esophagus is underestimated, but
preneoplasia is rare-correlation with Barrett's esophagus. BMC
Gastroenterol. 17:872017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin Y, Li H, Feng J, Zheng K, Yoshida E,
Wang L, Wu Y, Guo X, Shao X and Qi X: Prevalence and clinical and
endoscopic characteristics of cervical inlet patch (heterotopic
gastric mucosa): A systematic review and meta-analysis. J Clin
Gastroenterol. 56:e250–e262. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ciocalteu A, Popa P, Ionescu M and Gheonea
DI: Issues and controversies in esophageal inlet patch. World J
Gastroenterol. 25:4061–4073. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akbayir N, Alkim C, Erdem L, Sökmen HM,
Sungun A, Başak T, Turgut S and Mungan Z: Heterotopic gastric
mucosa in the cervical esophagus (inlet patch): Endoscopic
prevalence, histological and clinical characteristics. J
Gastroenterol Hepatol. 19:891–896. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rusu R, Ishaq S, Wong T and Dunn JM:
Cervical inlet patch: New insights into diagnosis and endoscopic
therapy. Frontline Gastroenterol. 9:214–220. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Orosey M, Amin M and Cappell MS: A 14-year
study of 398 esophageal adenocarcinomas diagnosed among 156,256
EGDs performed at two large hospitals: An inlet patch is proposed
as a significant risk factor for proximal esophageal
adenocarcinoma. Dig Dis Sci. 63:452–465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang P, McKinley MJ, Sporrer M and Kahn E:
Inlet patch: Prevalence, histologic type, and association with
esophagitis, Barrett esophagus, and antritis. Arch Pathol Lab Med.
128:444–447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coleman HG, Xie SH and Lagergren J: The
epidemiology of esophageal adenocarcinoma. Gastroenterology.
154:390–405. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sawas T and Katzka DA: Esophageal
adenocarcinoma phenotypes and risk factors. Curr Opin
Gastroenterol. 38:423–427. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kitasaki N, Hamai Y, Yoshikawa T, Emi M,
Kurokawa T, Hirohata R, Ohsawa M and Okada M: Recurrent esophageal
adenocarcinoma derived from ectopic gastric mucosa: A case report.
Thorac Cancer. 13:876–879. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ito M, Dobashi A, Komori M, Sugimura S,
Aizawa D, Takahashi K, Tanishima Y and Sumiyama K: Lymph node
metastasis after endoscopic submucosal dissection of a superficial
esophageal adenocarcinoma arising from the ectopic gastric mucosa
of the cervical esophagus: A case report. DEN Open. 3:e2142023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakao E, Fujisaki J, Nakano K, Kawachi H,
Narimiya N, Suzuki S, Namikawa K, Tokai Y, Yoshimizu S, Horiuchi Y,
et al: Early esophageal adenocarcinoma with non-Barrett's columnar
epithelium origin: Two case reports and a literature review. Intern
Med. 62:1939–1946. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohki D, Tsuji Y, Yamazawa S, Ushiku T and
Tateishi K: Gastrointestinal: Esophageal adenocarcinoma arising
from circumferential ectopic gastric mucosa: A case report. J
Gastroenterol Hepatol. 37:472022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikeda R, Hirasawa K, Ozeki Y, Sawada A,
Nishio M, Fukuchi T, Sato C and Maeda S: Cervical esophageal
adenocarcinoma of intestinal type in ectopic gastric mucosa. DEN
Open. 3:e1412022. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tanaka M, Ushiku T, Ikemura M, Junji
Shibahara J, Seto Y and Fukayama M: Esophageal adenocarcinoma
arising in cervical inlet patch with synchronous Barrett's
esophagus-related dysplasia. Pathol Int. 64:397–401. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stiles BM, Mirza F, Port JL, Lee PC, Paul
S, Christos P and Altorki NK: Predictors of cervical and recurrent
laryngeal lymph node metastases from esophageal cancer. Ann Thorac
Surg. 90:1805–1811. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
von Rahden BHA, Stein HJ, Becker K and
Siewert RJ: Esophageal adenocarcinomas in heterotopic gastric
mucosa: Review and report of a case with complete response to
neoadjuvant radiochemotherapy. Dig Surg. 22:107–112. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sjoquist KM, Burmeister BH, Smithers BM,
Zalcberg JR, Simes RJ, Barbour A and Gebski V; Australasian
Gastro-Intestinal Trials Group, : Survival after neoadjuvant
chemotherapy or chemoradiotherapy for resectable oesophageal
carcinoma: An updated meta-analysis. Lancet Oncol. 12:681–692.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ronellenfitsch U, Schwarzbach M, Hofheinz
R, Kienle P, Kieser M, Slanger TE, Burmeister B, Kelsen D,
Niedzwiecki D, Schuhmacher C, et al: Preoperative
chemo(radio)therapy versus primary surgery for gastroesophageal
adenocarcinoma: Systematic review with meta-analysis combining
individual patient and aggregate data. Eur J Cancer. 49:3149–3158.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang DB, Zhang X, Han HL, Xu YJ, Sun DQ
and Shi ZL: Neoadjuvant chemoradiotherapy could improve survival
outcomes for esophageal carcinoma: A meta-analysis. Dig Dis Sci.
57:3226–3233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vrînceanu D, Dumitru M, Ştefan AA,
Mogoantă CA and Sajin M: Giant pleomorphic sarcoma of the tongue
base-a cured clinical case report and literature review. Rom J
Morphol Embryol. 61:1323–1327. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Warner S, Chang YH, Paripati H, Ross H,
Ashman J, Harold K, Day R, Stucky CC, Rule W and Jaroszewski D:
Outcomes of minimally invasive esophagectomy in esophageal cancer
after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 97:439–445.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tagkalos E, van der Sluis PC, Berlth F,
Poplawski A, Hadzijusufovic E, Lang H, van Berge Henegouwen MI,
Gisbertz SS, Müller-Stich BP, Ruurda JP, et al: Robot-assisted
minimally invasive thoraco-laparoscopic esophagectomy versus
minimally invasive esophagectomy for resectable esophageal
adenocarcinoma, a randomized controlled trial (ROBOT-2 trial). BMC
Cancer. 21:10602021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakamura K, Kato K, Igaki H, Ito Y,
Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, et
al: Three-arm phase III trial comparing cisplatin plus 5-FU (CF)
versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy
with CF (CF-RT) as preoperative therapy for locally advanced
esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol.
43:752–755. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ajani JA, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al: Clinical benefit with docetaxel plus fluorouracil and
cisplatin compared with cisplatin and fluorouracil in a phase III
trial of advanced gastric or gastroesophageal cancer
adenocarcinoma: The V-325 study group. J Clin Oncol. 25:3205–3209.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Walsh TN, Noonan N, Hollywood D, Kelly A,
Keeling N and Hennessy TP: A comparison of multimodal therapy and
surgery for esophageal adenocarcinoma. N Engl J Med. 335:462–467.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ychou M, Boige V, Pignon JP, Conroy T,
Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM,
Saint-Aubert B, et al: Perioperative chemotherapy compared with
surgery alone for resectable gastroesophageal adenocarcinoma: An
FNCLCC and FFCD multicenter phase III trial. J Clin Oncol.
29:1715–1721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shapiro J, van Lanschot JJB, Hulshof MCCM,
van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven
HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al:
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for
oesophageal or junctional cancer (CROSS): Long-term results of a
randomised controlled trial. Lancet Oncol. 16:1090–1098. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grizzi G, Petrelli F, Di Bartolomeo M,
Viti M, Texeira Moraes M, Luciani A, Passalacqua R, Ghidini M,
Tomasello G, Baiocchi GL and Celotti A: Preferred neoadjuvant
therapy for gastric and gastroesophageal junction adenocarcinoma: A
systematic review and network meta-analysis. Gastric Cancer.
25:982–987. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim S, Paget-Bailly S, Messager M, Nguyen
T, Mathieu P, Lamfichekh N, Fein F, Fratté S, Cléau D, Lakkis Z, et
al: Perioperative docetaxel, cisplatin, and 5-fluorouracil compared
to standard chemotherapy for resectable gastroesophageal
adenocarcinoma. Eur J Surg Oncol. 43:218–225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Al-Batran SE, Homann N, Pauligk C, Goetze
TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, et al:
Perioperative chemotherapy with fluorouracil plus leucovorin,
oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus
cisplatin and epirubicin for locally advanced, resectable gastric
or gastrooesophageal junction adenocarcinoma (FLOT4): A randomised,
phase 2/3 trial. Lancet. 393:1948–1957. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu H, Minamide T and Yano T: Role of
photodynamic therapy in the treatment of esophageal cancer. Dig
Endosc. 31:508–516. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hayashi T, Asahina Y, Nakanishi H,
Terashima T, Okamoto K, Yamada S, Takatori H, Kitamura K, Mizukoshi
E, Ninomiya I and Kaneko S: Evaluation of the efficacy and safety
of salvage photodynamic therapy by talaporfin sodium for cervical
esophageal cancers and lesions larger than 3 cm. Esophagus.
18:645–654. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Komanduri S, Muthusamy VR and Wani S:
Controversies in endoscopic eradication therapy for Barrett's
esophagus. Gastroenterology. 154:1861–1875.e1. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Overholt BF, Wang KK, Burdick JS,
Lightdale CJ, Kimmey M, Nava HR, Sivak MV Jr, Nishioka N, Barr H,
Marcon N, et al: Five-year efficacy and safety of photodynamic
therapy with photofrin in Barrett's high-grade dysplasia.
Gastrointest Endosc. 66:460–468. 2007. View Article : Google Scholar : PubMed/NCBI
|
